Navigation Links
Mayo Clinic researchers find that protein believed to protect against cancer has a Mr. Hyde side
Date:9/3/2009

JACKSONVILLE, Fla. In a biological rendition of fiction's Strange Case of Dr. Jekyll and Mr. Hyde, researchers from the Mayo Clinic campus in Florida and Harvard Medical School have found that a protein thought to protect against cancer development can actually spur the spread of tumors.

The scientists, reporting in the Sept. 3 issue of Molecular and Cellular Biology, found that FOXO3a, a transcription factor that regulates gene expression, becomes active when growing cancer cells begin to starve. Their research suggests that this protein then turns on molecular switches that allow the cancer cells to invade surrounding tissues.

"This is a complete reversal of what everyone thought about FOXO3a that we should find a way to activate this transcription factor so as to fight cancer growth," says cancer biologist Peter Storz, Ph.D., the study's lead investigator from Mayo Clinic in Florida.

Findings from the study, which was funded in part by the Florida Department of Health, illustrate the growing recognition in the research community that proteins can play multiple roles with respect to tumor progression, he says.

"More and more we see that, when it comes to cancer, proteins can have split personalities," Dr. Storz says. "Proteins once firmly believed to be tumor suppressors that protect against cancer development have recently been found to act as oncogenes, or cancer promoters, in certain cancers and in some biological circumstances. We now understand that proteins behave in different ways, depending on the cellular context."

Dr. Storz and his laboratory colleagues focus on understanding how cancer cells spread. This study builds upon a recent finding by collaborating author Alex Toker, Ph.D., associate professor, Department of Pathology, Harvard Medical School. Dr. Toker had found that Akt, a protein that protects tumor cells from programmed cell death and induces proliferation of cancer, in some circumstances also inhibits tumor cell invasion. "This is an important protein that dogma said acts as an oncogene but which Dr. Toker demonstrated could also inhibit cancer spread, and thus may act as a suppressor for metastasis," Dr. Storz says.

Because Akt is an important negative-regulator of FOXO3a, the team looked at whether FOXO3a was actually the player with the Jekyll and Hyde split personality. They found that the transcription factor does indeed revert to its dangerous persona when a cancer cell becomes starved. "Our hypothesis is that if a cancer cell doesn't get the nutrients it needs, it turns on FOXO3a, which leads to the migration and invasion of tumor cells into areas with better growth conditions," Dr. Storz says. "This data fits neatly with Dr. Toker's findings about Akt, because Akt targets FOXO3a."


'/>"/>

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Related biology news :

1. General tumor marker test now offered by GenWay clinical laboratory
2. Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development
3. Antibody targeting of glioblastoma shows promise in preclinical tests, say Lombardi researchers
4. $20 million NIH grant to transform clinical research at UIC
5. Systems biology recommended as a clinical approach to cancer
6. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
7. Clinical trial shows quadriplegics can operate powered wheelchair with tongue drive system
8. Versartis presents positive preclinical data on 2 product candidates at ENDO 09
9. Brain-computer interface, developed at Brown, begins new clinical trial
10. REGiMMUNE presents enhanced efficacy data in preclinical transplantation models
11. SNMs clinical trials network gains added support from industry leader
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2019)... N.J. and HERCULES, Calif. (PRWEB) , ... November ... ... of solutions for epigenetics research and sample preparation, and Bio-Rad Laboratories, Inc. (NYSE: ... products, today announced a partnership in which Diagenode will offer Single-Cell ATAC-Seq (scATAC-Seq) ...
(Date:11/14/2019)... ... November 13, 2019 , ... Personalized Stem Cells, Inc (“PSC”), ... FDA approved clinical trial for stem cell treatment of knee osteoarthritis . The ... as a subsidiary of VetStem Biopharma. , In July of 2019, PSC received ...
(Date:11/12/2019)... ... November 12, 2019 , ... The Arnold and Mabel Beckman ... research institutions for its Instrumentation Grant for Advanced Light-Sheet Microscopy and Data ... site for the acquisition of instrumentation, development and maintenance; support for data science ...
Breaking Biology News(10 mins):
(Date:12/4/2019)... (PRWEB) , ... December 03, 2019 , ... A new ... have shown can reduce and even reverse fibrosis (scar tissue) buildup – also improves ... Stanford University School of Medicine, was conducted on mice. , The tumor-destroying capabilities ...
(Date:12/2/2019)... ... December 02, 2019 , ... Registration is now ... Meeting, which will be held at the Hynes Convention Center May 12-15, 2020, in ... therapy and brings together scientists, physicians, patient advocates, and other stakeholders with the goal ...
(Date:11/22/2019)... ... November 21, 2019 , ... Lajollacooks4u is preparing for another busy ... company already scheduled several of its popular cooking classes and team-building events, but the ... The company’s Holiday Parties have been a favorite for companies of all sizes since ...
(Date:11/12/2019)... ... 2019 , ... REPROCELL Inc. a stem cell and drug ... to provided preclinical screening and drug sensitivity for its portfolio of oncology drugs. ... unique and genetically edited cell lines from various tumors. The data generated from ...
Breaking Biology Technology: